Evidence map›Paper›PMID 36549983›Full record

ArticleMayo Clinic proceedings2023

Cardiovascular Risk and Diseases in Patients With and Without Leptin-Melanocortin Pathway Variants.

Lizeth Cifuentes, Alejandro Campos, Daniel Sacoto, Wissam Ghusn, Alan De la Rosa, Fauzi Feris, Alison McRae, Joshua T Bublitz, Maria D Hurtado, Janet Olson and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mayo Clinic proceedings, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Lizeth CifuentesPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN.
Alejandro CamposPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN.
Daniel SacotoPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN.
Wissam GhusnPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN.
Alan De la RosaPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN.
Fauzi FerisPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN.
Alison McRaePrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN.
Joshua T BublitzDivision of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
Maria D HurtadoPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN; Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic Health System, La Crosse, WI.
Janet OlsonDivision of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
Andres AcostaPrecision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN. Electronic address: acosta.andres@mayo.edu.
Mayo Clinic in Arizona · USMayo Clinic in Florida · USMayo Clinic · USMayo Clinic Health System · US

Funding

Mechanisms of Enteroendocrine L-Cell Dysfunction and Bile Adaptations to Weight LossK23DK114460 · NIDDK · MAYO CLINIC ROCHESTER · PI ACOSTA, ANDRES J · 2018 to 2022
$980k
NIDDK NIH HHS K23 DK114460
6 · The paper itself

Abstract

objectiveTo study differences in cardiovascular risk factors and diseases between patients with and without genetic variants in the leptin-melanocortin pathway.

methodsA cross-sectional study of patients with a history of severe obesity genotyped in June 2019 as participants of the Mayo Clinic Biobank was conducted in March 2022 to assess differences in cardiovascular risk and diseases between carriers of a heterozygous variant in the leptin-melanocortin pathway and noncarriers. Cardiovascular risk factors included hypertension, diabetes, dyslipidemia, and smoking. Cardiovascular disease includes coronary artery disease, peripheral artery disease, and cerebrovascular accidents. Patients with a history of bariatric surgery were excluded. We used logistic regression models to estimate the odds ratio and 95% CI, adjusting for age, body mass index (BMI), and sex.

resultsAmong a total of 168 carriers (8%; 121 [72%] female; mean [SD] age, 65.1 [14.9] years; BMI, 44.0 [7.4] kg/m

conclusionDespite having similar body weight and BMI, carriers of heterozygous variants in the leptin-melanocortin pathway had higher rates of hypertension than noncarriers. These findings point to an association between hypertension and leptin-melanocortin pathway variants.

Indexed as

Cardiovascular DiseasesDiabetes MellitusDyslipidemiasHypertensionAgedBody Mass IndexCross-Sectional StudiesFemaleHeart Disease Risk FactorsHumansLeptinMaleMelanocortinsMiddle AgedRisk FactorsLeptinMelanocortins

Identifiers

PMID36549983
PMCPMC10079551
OpenAlexW4312038445

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.